Targeting protein kinase B/Akt signaling with vanadium compounds for cardioprotection

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 10, 2008, Pages 1217-1227

  Bhuiyan, Md Shenuarin ^a   Shioda, Norifumi ^a   Fukunaga, Kohji ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Bim; Fas ligand; Forkhead transcription factor; Myocardial ischemia reperfusion; Protein kinase B Akt; VO(OPT)

Indexed keywords

BIM PROTEIN; BIS(1 OXY 2 PYRIDINETHIOLATO)OXOVANADIUM; FAS LIGAND; FLICE INHIBITORY PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; VANADATE SODIUM; VANADYL DERIVATIVE; VANADYL SULFATE;

APOPTOSIS; AREA UNDER THE CURVE; CELL PROTECTION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; NONHUMAN; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; TERATOGENICITY;

ANIMALS; CARDIOTONIC AGENTS; MYOCARDIAL REPERFUSION INJURY; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; VANADIUM COMPOUNDS;

EID: 54349100477     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.10.1217     Document Type: Review

References (83)

1. Oudit GY, Sun H, Kerfant BG, et al. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 2004;37:449-71
2. Matsui T, Tao J, del Monte F, et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 2001;104:330-5
3. Ou H, Yan L, Mustafi D, et al. The vanadyl (VO2+) chelate bis(acetylacetonato) oxovanadium(IV) potentiates tyrosine phosphorylation of the insulin receptor. J Biol Inorg Chem 2005;10:874-86
4. Theberge J F, Mehdi MZ, Pandey SK, Srivastava AK. Prolongation of insulin-induced activation of mitogen-activated protein kinases ERK 1/2 and phosphatidylinositol 3-kinase by vanadyl sulfate, a protein tyrosine phosphatase inhibitor. Arch Biochem Biophys 2003;420:9-17
5. Mehdi MZ, Srivastava AK. Organo-vanadium compounds are potent activators of the protein kinase B signaling pathway and protein tyrosine phosphorylation: mechanism of insulinomimetics. Arch Biochem Biophys 2005;440:158-64
6. Takada Y, Hashimoto M, Kasahara J, et al. Cytoprotective effect of sodium orthovanadate on ischemia/reperfusion-induced injury in the rat heart involves Akt activation and inhibition of fodrin breakdown and apoptosis. J Pharmacol Exp Ther 2004;311:1249-55
7. Liem DA, Gho CC, Gho BC, et al. The tyrosine phosphatase inhibitor Bis (Maltolato)oxovanadium attenuates myocardial reperfusion injury by opening ATP-sensitive potassium channels. J Pharmacol Exp Ther 2004;309:1256-62
8. Bhuiyan MS, Shibuya M, Shioda N, et al. Cytoprotective effect of bis( 1-oxy-2 pyridinethiolato)oxovanadium (IV) on myocardial ischemia/ reperfusion injury elicits inhibition of Fas ligand and Bim expression and elevation of FLIP expression. Eur J Pharmacol 2007;571:180-8
9. Bhuiyan MS, Takada Y, Shioda N, et al. Cardioprotective effect of vanadyl sulfate on ischemia/reperfusion-incluced injury in rat heart in vivo is mediated by activation of protein kinase B and induction of FLICE-inhibitory protein. Cariovasc Ther 2008;26:10-23
10. Fryer RM, Schultz JE, Hsu AK, Gross GJ. Importance of PKC and tyrosine kinase in single or multiple cycles of preconditioning in rat hearts Am J Physiol 1999;276:1229-35
11. Przyklenk K, Kloner RA. Ischemic preconditioning: exploring the paradox. Prog Cardiovasc Dis 1998;40:517-47
12. Vahlhaus C, Schulz R, Post H, et al. Prevention of ischemic preconditioning only by combined inhibition of protein kinase C and protein tyrosine kinase in pigs. J Mol Cell Cardiol 1998;30:197-209
13. Geraldes CF, Castro MM, Sherry AD, Ramasamy R. Influence of vanadate on glycolysis, intracellular sodium and pH in perfused rat hearts. Mol Cell Biochem 1997;170:53-63
14. Liu H, McNeill JH. Effects of vanadium treatment on the alterarions of cardiac glycogen phosphorylase and phosphorylase kinase in streptozotocin-induced chronic diabetic rats Can J Physiol Pharmacol 1994;72:1537-43
15. Ramanadham S, Brownsey RW, Cros GH, et al. Sustained prevention of myocardial and metabolic abnormalities in diabetic rats following withdrawal from oral vanadyl treatment. Metabolism 1989;38:1022-8
16. Bhanot S, McNeill JH. Vanadyl sulfate lowers plasma insulin and blood pressure in spontaneously hypertensive rats. Hypertension 1994;24:625-32
17. Bhanot S, McNeill JH, Bryer-Ash M. Vanadyl sulfate prevents fructose-induced hyperinsulinemia and hypertension in rats. Hypertension 1994;23:308-12
18. Bhanot S, Michoulas A, McNeill JH. Antihypertensive effects of vanadium compounds in hyperinsulinemic, hypertensive rats. Mol Cell Biochem 1995;153:205-9
19. Elberg G, Li J, Shechter Y. Vanadium activates or inhibits receptor and non-receptor protein tyrosine kinases in cell-free experiments, depending on its oxidation state. J Biol Chem 1994;269:9521-7
20. Boscolo P, Carmignani M, Volpe AR, et al. Renal toxicity and arterial hypertension in rats chronically exposed to vanadate. Environ Med 1994;51:500-3
21. Llobet JM, Domingo JL. Acute toxicity of vanadium compounds in rats and mice. Toxicol Lett 1984;23:227-31
22. Sakurai H, Shimomura S, Fukuzawa K, Ishizu K. Detection of oxovanadium (IV) and characterization of its ligand environment in subcellular fractions of the liver of rats treated with pentavalent vanadium (V). Biochem Biophys Res Commun 1980;96:293-8
23. Macara IG, Kustin K, Cantley LC Jr. Glutathione reduces cytoplasmic vanadate: mechanism and physiological implications. Biochim Biophys Acta 1980;62:95-106
24. Shi X, Dalal SN. Superoxide-independent reduction of Vanadate by rat liver microsomes/NAD(P)H: Vanadate reductase activity. Arch Biochem Biophys 1992;295(1):70-5
25. Elberg G, Li J, Shechter Y. Vanadium activates or inhibits receptor and non-receptor prtein tyrosine kinases in cell-free experiments, depending on its oxidation state. J Biol Chem 1994;269:9521-7
26. Willsky GR, White DA, McCabe BC. Metabolism of added orthovanadate to vanadyl and high-molecular-weight vanadates by Saccharomyces cerevisiae. J Biol Chem 1984;259(21):13273-81
27. Huyer G, Liu S, Kelly J, et al. Mechanism of inhibition of protein-tyrosine phosphatases by Vanadate and pervanadate. J Biol Chem 1997;272:843-51
28. Ronzani N, Stephan L, Hasselbach W. Pressure effects on the binding of vanadate to the sarcoplasmic reticulum calcium transport enzyme. Eur J Biochem 1991;201:265-72
29. Carmeli C, Tadmor O, Lifshitz Y, et al. Inhibition of chloroplast CF1-ATPase by vanadate. FEBS Lett 1992;299:229-30
30. Cantley LC Jr, Josephson L, Warner R, et al. Vanadate is a potent (Na, K)-ATPase inhibitor found in ATP derived from muscle. J Biol Chem 1977;252:7421-3
31. Dafnis E, Spohn M, Lonis B, et al. Vanadate causes hypokalemic distal renal tubular acidosis. Am J Physiol 1992;262:F449-53
32. Sakurai H, Tsuchiya K, Nukatsuka M, et al. Insulin-like effect of vanadyl ion on streptozotocin-induced diabetic rats. J Endocrinol 1990;126:241-459
33. Reul BA, Amin SS, Buchet JP, et al. Effect of vanadium complexes with organic ligands on glocuse metabolism: a comparison study in diabetic rats. Br J Pharmacol 1999;126:467-77
34. Sakurai H, Sano H, Takino T, Yasui H. An orally active antidiabetic vanadyl complex, bis(1 -oxy-2-pyridinethiolaro) oxovanadium(IV), with VO(S202) coordination mode; in vitro and in vivo evaluations in rats. J Inorg Biochem 2000;80:99-105
35. Takeshita S, Kawamura I, Yasuno T, et al. Amelioration of insulin resistance in diabetic ob/ob mice by a new type of orally active insulin-mimetic vanadyl complex: bis(1-oxy-2-pyridinethiolato) oxovanadium (IV) with VO(S202) coordination mode. J Inorg Biochem 2001; 85:179-86
36. Gottilieb RA, Engler RL. Apoptosis in myocardial ischemia-reperfusion. Ann NY Acad Sci 1999;874:412-26
37. Bhuiyan MS, Fukunaga K. Inhibition of HtrA2/Omi ameliorates heart dysfunction following ischemia/reperfusion injury in rat heart in vivo. Eur J Pharmacol 2007;557:168-77
38. Swarup G, Cohen S, Garbers DL. Inhibition of membrane phosphotyrosyl-protein phosphatases activity by Vanadate. Biochem Biophys Res Commun 1982;107:1104-9
39. Shioda N, Ishigami T, Han F, et al. Activation of phosphotidylinositol 3-kinase/protein kinase B pathway by a vanadyl compound mediates its neuroprotective effect in mouse brain ischemia. Neuroscience 2007;148:221-9
40. Vijaya S, Crane FL, Ramasarma T. A Vanadate-stimulated NADH oxidase in erythrocyte membrane generates hydrogen peroxide. Mol Cell Biochem 1984;62:175-85
41. Cittadini A, Monti MG, Iaccarino G, et al. Adenoviral gene transfer of Akt enhances myocardial contractility and intracellular calcium handling. Gene Ther 2006;313:8-19
42. Gnecchi M, He H, Liang OD, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005;11:367-8
43. Mangi AA, Noiseux N, Kong D, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003;9:1195-201
44. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of bad couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41
45. Fukunaga K, Kawano T. Akt is a molecular target for signal transduction therapy in brain ischemia insult. J Pharmacol Sci 2003;92:317-27
46. Lizcano JM, Morrice N, Cohen P. Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155. Biochem J 2000;349:547-57
47. Tan Y, Demeter MR, Ruan H, Comb MJ. BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival. J Biol Chem 2000;275:25865-9
48. Masters SC, Yang H, Datta SR, et al. 14-3-3 inhibits Bad-induced cell death through in teraction with serine- 136. Mol Pharmacol 2001; 60:1325-31
49. Kawano T, Morioka M, Yano S, et al. Decreased Akt activity is associated with activation of Forkhead transcription factor after transient forebrain ischemia in gerbil hippocampus. J Cereb Blood Flow Metab 2002;22:926-34
50. Fukunaga K, Ishigami T, Kawano T. Transcriptional regulation of neuronal genes and its effect on neuronal functions: expression and function of forkhead transcription factors in neurons. J Pharmacol Sci 2005;98:205-11
51. Zhang X, Gan L, Pan H, et al. Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding. J Biol Chem 2002;277:45276-84
52. Papanicolaou KN, Izumiya Y, Waish K. Forkhead transcription factors and cardiovascular biology. Circ Res 2008;102:16-31
53. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-68
54. Dijkers PF, Medema RH, Lammers JWJ, et al. Expression of the pro-apoptotic Bcl02 family member Bim is regulated by the forkhead transcription factor FKHRL-1. Curr Biol 2000;10:1201-4
55. Kawano T, Fukunaga K, Takeuchi Y, et al. Neuroprotective effect of sodium orthovanadate on delayed neuronai death after transient forebrain ischemia in gerbil hippocampus. J Cereb Blood Flow Metab 2001;21:1268-80
56. Skurk C, Maatz H, Kim HS, et al. The Akt-regulated Forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J Biol Chem 2004;279:1513-25
57. Suhara T, Mano T, Oliveira BE, Walsh K. Phosphatidylinositol 3-Kinase/ Akt signaling controls endothelial cell sensitivity to Fas-Mediated apoptosis via regulation of Flice-Inhibitory Protein (FLIP). Circ P, Res 2001;89:13-9
58. Rasper DM, Vaillancourt JP, Hadano S, et al. Cell death attenuation by 'Usurpin', a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. Cell Death Differ 1998;5:271-88
59. Imanishi T, Murry CE, Reinecke H, et al. Cellular FLIP is expressed in cardiomyocytes and down-regulated in TUNEL-positive grafted cardiac tissues. Cardiovasc Res 2000;48:101-10
60. Srivastava AK. Anti-diabetic and toxic effects of vanadium compounds. Mol Cell Biochem 2000;206:177-82
61. Srivastava AK, Mehdi MZ. Insulino-mimetic and anti-diabetic effects of vanadium compounds. Diabet Med 2005;22:2-13
62. Strout HV, Vicario PP, Saperstein R, et al. The insulin-mimetic effect of vanadate is not correlated with insulin receptor tyrosine kinase activity or phosphorylation in mouse diaphragm in vivo. Endocrinology 1989;124:1918-24
63. Meyerovitch J, Farfel Z, Sack J, et al. Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats: characterization and mode of action. J Biol Chem 1987;262:6658-62
64. Domingo JL, Gomez M, Sanchez DJ, et al. Toxicology of vanadium compounds in diabetic rats: the action of chelating agents on vanadium accumulation. Mol Cell Biochem 1995;153:233-40
65. Domingo JL. Vanadium and tungsten derivatives as antidiabetic agents: a review of their toxic effects. Biol Trace Elem Res 2002;88:97-112
66. Faure R, Vincent M, Dufour M, et al. Arrest at the G2/M transition of the cell cycle by protein-tyrosine phosphatase inhibition: studies on a neuronal anda glial cell line. J Cell Biochem 1995;59:389-401
67. Fantus IG, Tsiani E. Multifunctional actions of vanadium compounds on insulin signaling pathways: evidence for preferential enhancement of metabolic versus mitogenic effects. Mol Cell Biochem 1998;182:109-19
68. Djordjevic C. Antitumor activity of vanadium compounds. Met Ions Biol Syst 1995;31:595-616
69. Liasko R, Kabanos TA, Karkabounas S, et al. Beneficial effects of a vanadium complex with cysteine, administered at low doses on benzo (alpha) pyrene-induced leiomyosarcomas in Wistar rats. Anticancer Res 1998;18:3609-13
70. Blondel O, Bailbe D, Portha B. In vivo insulin resistance in streptozotocin diabetic rats - evidence for reversal following oral vanadate treatment. Diabetologia 1989;32:185-90
71. Al-Bayati MA, Giri SN, Raah OG. Time and dose response study of the effects of Vanadate in rats: changes in blood cells, serum enzymes, protein, cholesterol, glucose, calcium and inorganic phosphate. J Environ Pathol Toxicol Oncol 1990;10:206-13
72. Bishayee A, Cecchin F. Time course effects of vanadium supplements on cytosolic reduced glutathione level and glutathione S-transferase activity. Biol Trace Elem Res 1995;48:275-85
73. Mongold JJ, Cros GH, Vian L, et al. Toxicological aspects of vanadyl sulphate on diabetic rats: effects on vanadium levels and pancreatic B-cell morphology. Pharmacol Toxicol 1990;67:192-8
74. Goldfine AB, Simonson DC, Folli F, et al. In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. Mol Cell Biochem 1995;153:217-31
75. Cohen N, Halberstam M, Shlimovich P, et al. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patient with non-insulin-dependent diabetes mellitus. J Clin Invest 1995;95:2501-9
76. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest 1985;76:1713-9
77. Park JL, Lucchesi BR. Mechanisms of myocardial reperfusion injury. Ann Thorac Surg 1999;68:1905-12
78. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002;105:656-62
79. Tong H, Chen W, Steenbergen C, et al. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res 2000;87:309-15
80. Zhu M, Feng J, Lucchinetti E, et al. Ischemic postconditioning protects remodeled myocardium via the PI3K-PKB/Akt reperfusion injury salvage kinase pathway. Cardiovasc Res 2006;72(1):152-62
81. Duan J, Zhang HY, Adkins SD, et al. Impaired cardiac function and IGF-I response in myocytes from calmodulin-diabetic mice: role of Akt and RhoA. Am J Physiol Endocrinol Metab 2003;284(2):E366-76
82. Haq S, Choukroun G, Lim H, et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 2001;103:670-7
83. Taniyama Y, Walsh K. Elevated myocardial Akt signaling ameliorates doxorubicin-induced congestive heart failure and promotes heart growth. J Mol Cell Cardiol 2002;34:1241-7